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Abstract
Background: The randomized placebo-controlled IFIGENIA-trial demonstrated that therapy with
high-dose N-acetylcysteine (NAC) given for one year, added to prednisone and azathioprine,
significantly ameliorates (i.e. slows down) disease progression in terms of vital capacity (VC) (+9%)
and diffusing capacity (DLco) (+24%) in idiopathic pulmonary fibrosis (IPF). To better understand
the clinical implications of these findings we performed additional, explorative analyses of the
IFGENIA data set.
Methods: We analysed effects of NAC on VC, DLco, a composite physiologic index (CPI), and
mortality in the 155 study-patients.
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Results: In trial completers the functional indices did not change significantly with NAC, whereas
most indices deteriorated with placebo; in non-completers the majority of indices worsened but
decline was generally less pronounced in most indices with NAC than with placebo. Most
categorical analyses of VC, DLco and CPI also showed favourable changes with NAC. The effects
of NAC on VC, DLco and CPI were significantly better if the baseline CPI was 50 points or lower.
Conclusion: This descriptive analysis confirms and extends the favourable effects of NAC on lung
function in IPF and emphasizes the usefulness of VC, DLco, and the CPI for the evaluation of a
therapeutic effect. Most importantly, less progressed disease as indicated by a CPI of 50 points or
lower at baseline was more responsive to therapy in this study.
Trial Registration: Registered at http://www.ClinicalTrials.gov; number NCT00639496.
Introduction
Idiopathic pulmonary fibrosis (IPF) is a distinct clinical
and histopathologic entity, which accounts for approxi-
mately two thirds of the idiopathic interstitial pneumo-
nias (IIP), and is associated with a high median mortality
of 50% within 3 to 5 years [1-5]. The cause of this disease
is unknown [4,6]. In the absence of a satisfactory treat-
ment - except for lung transplantation in selected patients
- the joint consensus statement on IPF by the American
Thoracic Society and the European Respiratory Society
suggested prednisone plus azathioprine (or cyclophos-
phamide) as potential treatment for IPF [4]. Based on this
statement the recently published IFIGENIA trial used
prednisone plus azathioprine as a standard treatment for
all patients who were randomly assigned to receive addi-
tionally high-dose N-acetylcysteine (NAC) or placebo [7].
A treatment effect in favour of NAC was observed with a
statistically significant smaller decrease of vital capacity
(VC) (9%) and diffusing capacity (DLco) (24%) [7],
which was in line with a previous observation [8]. How-
ever, in view of a drop-out rate of ca. 30% (including
deaths) questions have been raised regarding the clinical
relevance and robustness of the treatment effect [9]. These
appropriate questions prompted us to perform addi-
tional, exploratory analyses of the data set. We evaluated
subgroups of completers versus non-completers for differ-
ences in treatment response. We also calculated the Com-
posite Physiologic Index (CPI), which uses the individual
values for VC (% pred.), DLco (% pred.) and FEV1 (%
pred.) to calculate the extent of fibrosis according to an
empirically developed equation [10]. Based on low or
high baseline CPI we compared treatment effects on
patients with less progressed or progressed disease. We
think that these additional exploratory analyses of the IFI-
GENIA data set offer a unique opportunity to provide
insight into the clinical course of the disease, to describe
the potential clinical benefit of antioxidant therapy using
NAC, and to explore the influence of disease severity at
baseline on outcome.
Methods
Overall Design
Using data from the IFIGENIA trial [7], we performed a
series of exploratory analyses of physiologic variables and
characteristics in patients receiving prednisone and aza-
thioprine as suggested by the ATS/ERS Statement [4] plus
either high-dose NAC or placebo. The IFIGENIA study was
a multinational, double-blind, randomized, placebo-con-
trolled, parallel-group trial. Study treatment consisted of
NAC (Zambon Group) 600 mg effervescent tablets t.i.d.
or matched placebo. Patients (18 to 75 years) with a his-
tological or radiological pattern typical for usual intersti-
tial pneumonia (UIP) [1,5] were included after active
exclusion of other diseases [4,7]. Patients were excluded
in whom the standard regimen with prednisone and aza-
thioprine was contraindicated or not justified (i.e. in sta-
ble patients) (full in- and exclusion criteria see reference
[7]).
The study was conducted according to GCP-ICH guide-
lines goverend by the Declaration of Helsinki and by
national regulations. The protocol was approved by the
local ethics committees. All patients gave written
informed consent and were free to withdraw at any time.
Regular monitoring and sample audits were performed at
the centers throughout the study. The study was designed
and analysed by 19 academic physicians experienced in
idiopathic pulmonary fibrosis, 1 independent statistician,
and three representatives of the sponsor. The sponsor held
the data but placed no limitations on study design, data
analysis, or the content of the manuscript. The main sta-
tistical analysis was performed by an independent statisti-
cal company (Innopharma, Milan, Italy).
Setting, Participants, and Randomization
Between March 2000 and July 2002 184 patients were
screened in 36 centers from six countries. Out of 182 eli-
gible patients twenty-seven were not included in the anal-
ysis: 5 patients withdrew consent before starting treatmentRespiratory Research 2009, 10:101 http://respiratory-research.com/content/10/1/101
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and 22 (12%) were excluded because the IPF-diagnosis
was not confirmed by the radiology or histology expert
committee [7]. Of the 155 patients included in the analy-
sis, 80 patients had been randomized to NAC and 75 to
placebo. There were no significant differences in baseline
characteristics [7].
Of these 155 patients, 108 (70%) completed the one year
study (57 on NAC, 51 on placebo). At baseline 8 patients
on NAC and 2 on placebo used long-term oxygen therapy
(LTOT); during the study, 3 additional patients on NAC
and 11 on placebo were started on LTOT. Forty-seven
patients (30%) did not complete the one year study: 32
patients (21%) withdrew for various reasons (16 on NAC
and 16 on placebo) and 15 (10%) died during the study:
7 (9%) on NAC, and 8 (11%) on placebo (p = 0.69).
Measurements
Vital capacity (VC), forced expired volume in 1 sec (FEV1)
and single-breath CO-diffusing capacity (DLco) were
measured and cardiopulmonary exercise testing was per-
formed according to ERS guidelines [11,12].
The composite physiologic index (CPI) was calculated
[10]: CPI = 91.0 - 0.65 × DLco(%pred) -0.53 VC(%pred)
+ 0.34 FEV1(%pred). CPI is in-between 20 and 80 points,
higher points indicating more fibrosis and poorer progno-
sis.
Statistical Analysis
As in the previous publication [7] the main statistical
analysis was based on a stepwise, fixed-effects analysis of
covariance using an iterative procedure including the
change from baseline as response variable, treatment and
country factors as fixed effects, baseline value as covariate
and following potential cofactors: smoking history (cur-
rent/ex-smokers vs. never-smokers), age (<65 years vs. ≥
65 years), duration of disease since diagnosis (≤ 6 vs. >6
months), DLco(≤ 40% vs. >40% predicted), VC (≤ 60%
vs. >60% predicted), sex (male vs. female), and whether a
biopsy had been performed. This former model was also
used for the analysis of the composite physiologic index
(CPI). For the analysis of CPI changes from baseline,
according to categorised baseline CPI, an ANOVA model
was used, including treatment and baseline CPI category
as fixed factors (basal CPI: ≤ 50; >50) and their interac-
tion; the cut-off value of 50 for basal CPI approximated
the median of baseline CPI (52.26). Using the median
itself did not impact on the results. Changing CPI cut-offs
by steps of one and five points, respectively, turned out to
show that a CPI of 50 points as cut-off appeared to be
optimal.
The analyses were based, as for the main analysis, on data
from all randomized patients who met the inclusion crite-
ria for the study, received the trial medication at least
once, and underwent at least baseline observation. Miss-
ing data were replaced by the last observation-carried-for-
ward (LOCF) method for all patients who underwent at
least one lung-function measurement after baseline [7].
As the data were reanalysed minor changes from the orig-
inal results occurred based on differences in adjustments
with baseline and covariates as well as rounding during
calculations. As a descriptive analysis the course of compl-
eters and non-completers was evaluated with respect to
treatment arm; the completer subset included all patients
with an assessment available at the 12 months final visit,
whereas non-completers were either drop-outs or patients
with a missing 12 months assessment.
Cardio-pulmonary exercise test derived variables were
analysed including only treatment as fixed effect and the
baseline value as a covariate.
For categorical analysis of lung function indices using var-
iable cut-off values, comparisons between NAC and pla-
cebo were performed using 2-sided Fisher exact tests. No
adjustment for multiple testing was performed, these
analyses being considered as exploratory.
Results
Analysis of VC, DLco, and CPI: last-observation-carried-
forward (LOCF) vs. Completers and Non-Completers
For the analysis of completers and non-completers (table
1 and 2) both groups did not differ significantly in demo-
graphic characteristics, but as could be expected, lung
function variables, PaO2 and CPI were worse in the non-
completers (table 1). By definition, the exposition to
study medication was 12 months in completers and
shorter in non-completers (5.4 ± 2.5 months). An individ-
ual analysis of the four data subsets (i.e. completers NAC/
Placebo and non-completers NAC/Placebo) revealed sig-
nificant declines in VC (l) and in DLco (mmol/min/kPa
and % predicted) in completers and non-completers with
placebo, whereas with NAC VC (l and % pred.) stayed sta-
ble in both completers and non-completers (table 2).
With NAC DLco (mmol/min/kPa and % pred.) remained
unchanged in completers and declined in the non-compl-
eters (table 2).
When formally assessing the differences between treat-
ment arms (ANCOVA model), a significant effect on VC of
0.18 ± 0.07 L and 4.80 ± 2.00% pred. was found when
using the LOCF method (p = 0.017). For the completers
the effect was smaller (0.09 ± 0.09 L, p = 0.34 and 1.93 ±
2.41% pred., p = 0.42) and more pronounced in non-
completers (0.22 ± 0.13 L, p = 0.099 and 7.26 ± 3.80%
pred., p = 0.069). For the DLco measurements NAC had a
statistically significant treatment effect in the completer
subset for absolute change and for % predicted (1.106 ±Respiratory Research 2009, 10:101 http://respiratory-research.com/content/10/1/101
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0.377 mmol/min/kPa, p = 0.0044 and 7.10 ± 2.64%
pred., p = 0.0087, respectively), but not so in the small
non-completer subset (0.380 ± 0.228 mmol/min/kPa, p =
0.11 and 3.573 ± 2.764% pred., p = 0.21).
We also calculated and analysed the Composite Physio-
logical Index (CPI) [10]. At baseline CPI mean ± SD was
similar in NAC vs. placebo treated patients (52.6 ± 9,8 vs.
50.93 ± 10.2, n.s.). An increase of the CPI indicates dis-
ease progression and was observed in the placebo group
using the LOCF method and also in the completer and
non-completer subsets using placebo, whereas NAC-
treated patients did not show significant disease progres-
sion in terms of the CPI in the LOCF and completer sub-
sets (table 2). In the non-completers disease progression
occurred with both, NAC (p = 0.010) and placebo (p <
Table 1: Baseline Characteristics of Completers and non-Completers:
Completers (N = 106) Non completers (N = 33) p value
All patients [n(%)] 106 (100.0%) 33 (100.0%)
Gender [n(%)] Male 74 (69.8%) 25 (75.8%) 0.5100
Female 32 (30.2%) 8 (24.2%)
Age (Year) 62.1 (9.0) 64.2 (8.3) 0.2219
Duration of symptoms (Month) 42.6 (44.4) 35.1 (34.9) 0.3812
Pretreatment [n(%)] No 52 (49.1%) 17 (51.5%) 0.8052
Yes 54 (50.9%) 16 (48.5%)
New diagnosis? [n(%)] No 71 (67.0%) 16 (48.5%) 0.0552
Yes 35 (33.0%) 17 (51.5%)
Surgical lung biopsy [n(%)] No 59 (55.7) 16 (48.5%) 0.1794
Yes 47 (44.3%) 17 (51.5%)
Baseline VC [l] 2.38 (0.72) 2.14 (0.65) 0.0901
Baseline DLCo [mmol/min/kPa] 4.03 (1.33) 3.07 (1.34) 0.0004 ***
Baseline TLC [l] 3.78 (0.98) 3.34 (0.89) 0.0261 *
Baseline PaO2 [mmHg] 73.23 (11.11) 66.98 (13.66) 0.0093 **
Baseline P(A-a)O2 [mmHg] 30.79 (13.82) 38.88 (25.17) 0.0376 *
Baseline FEV1/VC 0.840 (0.081) 0.841 (0.076) 0.9026
Baseline CPI 49.20 (10.71) 57.00 (9.75) 0.0003 ***
*: p < 0.05; **: p < 0.01; ***: p < 0.001;
Table 2: LOCF-method vs. Completers/non-Completers analyses of VC, DLco, and CPI: changes between last measurement and base 
line
LOCF-method Completers Non-Completers
Change from baseline † NAC PLA NAC PLA NAC PLA
VC (l) -0.057 -0.233 -0.062 -0.148 -0.207 -0.424
± SE ± 0.054 ± 0.057 ± 0.063 ± 0.069 ± 0.114 ± 0.119
n  = 7 16 8 5 55 11 6 1 7
p = 0.29 <0.0001 0.33 0.036 0.084 0.0017
VC (% pred.) -0.830 -5.634 -1.245 -3.178 -2.849 -10.109
± SE ± 1.426 ± 1.539 ± 1.655 ± 1.837 ± 3.241 ± 3.590
n  = 7 16 8 5 55 11 6 1 7
p = 0.56 0.0004 0.434 0.087 0.39 0.0098
DLco (mmol/min/kPa) -0.116 -0.652 0.339 -0.767 -0.832 -1.212
± SE ± 0.226 ± 0.226 ± 0.295 ± 0.322 ± 0.279 ± 0.222
n  = 6 86 3 4 84 62 0 1 7
p = 0.61 0.0047 0.25 0.02 0.0063 <0.0001
DLco(% pred.) -2.124 -7.361 -0.697 -7.801 -8.288 -11.861
± SE ± 1.809 ± 1.790 ± 2.239 ± 2.231 ± 3.034 ± 2.580
n  = 6 86 3 4 84 62 0 1 7
p = 0.24 <0.0001 0.76 0.0008 0.011 <0.0001
CPI 0.509 5.471 -1.086 5.065 6.854 9.867
± SE ± 1.474 ± 1.459 ± 1.812 ± 1.810 ± 2.488 ± 2.118
n  = 6 86 4 4 74 62 1 1 8
p = 0.73 0.0003 0.55 0.0065 0.010 <0.0001
† Least Square Means, relative SE and within groups p values were calculated from the model described in methodRespiratory Research 2009, 10:101 http://respiratory-research.com/content/10/1/101
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0.0001)(table 2). Again, the formal analysis of the treat-
ment effect between groups (ANCOVA model) was signif-
icant in favour of NAC when using the LOCF method (-
4.962 ± 1.607, p = 0.0025) and in the completer subset (-
6.151 ± 2.137, p = 0.0052); in the smaller non-completer
subset the same trend occurred (-3.014 ± 2.201, p = 0.20).
Analysis of cardio pulmonary exercise testing: LOCF vs. 
Completers and Non-Completers
Using the LOCF method and also in the completer sub-
group, significant declines of W'max, V'CO2max and V'O2
max during exercise were found with placebo, whereas no
significant changes occurred with NAC (table 3). The dif-
ference between the NAC and placebo groups was statisti-
cally significant in favour of NAC for V'CO2max (p =
0.033) using the LOCF method, and was statistically sig-
nificant favouring NAC for V'CO2max, V'O2max and
V'O2max % pred in the completer subset. The non-compl-
eter group was small for placebo (n ≤ 9) and NAC (n ≤ 7)
(table 3) and showed no significant differences.
Categorical analysis of VC, DLco and CPI and effect of 
baseline value of CPI
Categorical frequency analyses were performed at 5%
intervals for the changes in VC, DLco and CPI, to evaluate
how many patients would have achieved a specific prede-
fined endpoint. With NAC therapy significantly less
patients suffered a 5% or more deterioration of VC from
baseline as compared to placebo (40.8 vs. 61.8%, p =
0.018) (fig. 1A). Similarly, less patients with NAC therapy
as compared to placebo deteriorated with respect to DLco
at several levels: with any deterioration (59.7% vs. 76.7%,
p = 0.057), with more than 5% deterioration (53.7% vs.
73.3%, p = 0.028), with more than 35% deterioration
(9.0% vs. 23.3%, p = 0.030), and with more than 40%
deterioration (4.5% vs. 16.7%, p = 0.037) (fig. 1B). More-
over, a higher proportion of patients had improvements
in their DLco with NAC as compared to placebo at the
level of any improvement (40.3% vs. 23.3%, p < 0.05)
and with an improvement greater than 5% from baseline
(32.8% vs. 16.7%, p = 0.042). For CPI a similar trend was
observed.
Influence of baseline CPI on outcome
The baseline CPI influenced the outcome of therapy: the
patients with less advanced disease as indicated by a base-
line CPI ≤ 50 showed effects favouring NAC for changes of
the CPI itself (net effect after one year 8.11 points, p =
0.0002), the VC (net effect after one year 0.285 l, p =
0.0031), and the DLco (net effect after one year 1.042
mmol/min/kPa, p = 0.0015). In contrast, only small, sta-
tistically not significant trends (favouring NAC) were
observed in patients with a baseline CPI > 50 points (ΔCPI
0.560 points, n.s.; ΔVC 0.012 l, n.s.; ΔDLco 0.177 mmol/
min/kPa, n.s.). (See figures 2a-c).
Analysis of patients who survived/died
Of the total population of 155 patients 15 (10%) died; of
these 7 (9%) were in the NAC arm and 8 (11%) in the pla-
cebo arm. Only four out of 15 patients who died (26.7%)
had significant deterioration of PFT as defined in the ATS/
ERS-statement [4] prior to death, whereas eight (53.3%)
died within three months of treatment initiation without
follow-up PFTs; 4 of these latter 8 patients died from car-
diac disease, 3 succumbed to overwhelming infection,
and one died from respiratory failure. Analysis of patients
who survived or died with NAC or placebo showed no sta-
tistically significant differences in baseline demographics
Table 3: LOCF-method vs. Completers/non-Completers analyses of cardio pulmonary exercise test derived variables: changes 
between last measurement and baseline
LOCF-method Completers Non-Completers
NAC PLA NAC PLA NAC PLA
W'max (W) -3.693 -11.136 -1.259 -11.183 -19.262 -10.826
± SE ± 3.534 ± 3.382 ± 3.90 ± 3.849 ± 6.056 ± 4.944
n  = 4 44 83 83 96 9
p = 0.30 0.0014 0.75 0.0048 0.0079 0.0049
V'CO2max (L/min) 0.035 -0.138 0.0833 -0.141 -0.207 -0.128
± SE ± 0.0579 ± 0.0548 ± 0.0632 ± 0.0599 ± 0.127 ± 0.118
n  = 4 34 83 64 07 8
p = 0.55 0.014 0.19 0.022 0.13 0.30
V'O2max (L/min) 0.004 -0.121 0.0833 -0.141 -0.231 -0.105
± SE ± 0.050 ± 0.048 ± 0.056 0.054 0.108 0.095
n  = 4 44 83 73 97 9
p = 0.93 0.014 0.39 0.025 0.051 0.29
V'O2max (% pred.) -2.411 -8.628 -0.950 -9.473 -10.090 -4.993
± SE ± 2.554 ± 2.445 ± 2.786 ± 2.713 ± 5.180 ± 4.562
n  = 4 44 83 73 97 9
p = 0.35 0.0007 0.73 0.0008 0.073 0.29Respiratory Research 2009, 10:101 http://respiratory-research.com/content/10/1/101
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Categorical analyses in steps of 5% change from baseline dur- ing the one year study period Figure 1
Categorical analyses in steps of 5% change from base-
line during the one year study period. a: VC: Higher 
percentages of patients receiving NAC (black columns) 
showed any improvement and improvement of 5% or more 
as compared to baseline, whereas higher percentages of 
patients receiving placebo (white columns) showed any dete-
rioration or decreases of VC of more than 5, 10, 15, 20, and 
25% from baseline; this difference was significant at the 5% 
level (* p < 0.05 NAC vs plac). b: DLco#: A higher percent-
age of patients receiving NAC (black columns) showed 
improvement and a lower percentage of patients receiving 
NAC (black columns) showed deterioration of DLco as com-
pared to placebo (white columns). The differences were sta-
tistically significant at the levels <-40%, <-35%, <-5%, >5%, 
any deterioration, and any improvement (* p < 0.05 NAC vs 
plac for each of these comparisons). # numbers refer to 
DLco Hb corrected. c: CPI: A higher percentage of patients 
receiving NAC (black columns) showed improvement (i.e. 
decrease) and a lower percentage of patients receiving NAC 
(black columns) showed deterioration (i.e. increase) of the 
CPI as compared to placebo (white columns). The differ-
ences were statistically not significant.
Effects of NAC on CPI, VC, and DLco, depending on baseline  CPI being lower or higher than 50 points Figure 2
Effects of NAC on CPI, VC, and DLco, depending on 
baseline CPI being lower or higher than 50 points. a: 
Effect of NAC therapy on change in CPI from baseline, 
depending on baseline CPI being lower or higher than 50 
points. Black columns = NAC; white columns = placebo. LS 
means and 95% confidence interval for changes from baseline in 
a model including treatment and CPI category as fixed factors are 
plotted. * p = 0.0002 vs BL-CPI< = 50 NAC.  p = 0.016 vs. 
BL-CPI< = 50 Placebo b: Effect of NAC therapy on change in 
VC from baseline, depending on baseline CPI being lower or 
higher than 50 points. Black columns = NAC; white columns 
= placebo. LS means and 95% confidence interval for changes 
from baseline in a model including treatment and CPI category as 
fixed factors are plotted. * p = 0.0031 vs BL-CPI< = 50 NAC. p 
= 0.0066 between both NAC subunits. c: Effect of NAC 
therapy on change in DLco from baseline, depending on 
baseline CPI being lower or higher than 50 points. Black col-
umns = NAC; white columns = placebo. LS means and 95% 
confidence interval for changes from baseline in a model including 
treatment and CPI category as fixed factors are plotted. * p = 
0.0015 vs BL-CPI< = 50 NAC.  p = 0.067 vs. BL-CPI< = 50 
Placebo.Respiratory Research 2009, 10:101 http://respiratory-research.com/content/10/1/101
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between the four groups. However, P(A-a)O2 and CPI
were significantly higher at baseline in those patients who
died during the study (data not shown).
Discussion
This study extends the analysis of our previously pub-
lished IFIGENIA study [7] by categorical analysis of lung
function indices and description of completer/non-com-
pleter subsets. In addition we analysed the composite
physiologic index (CPI) which was especially designed
and validated to represent disease extent on HRCT and to
correct for coexisting emphysema and which has also
been shown to be a predictor of prognosis [10,13]. The
CPI has advantages over scoring system as proposed by
Watters et al [14] and by King et al. [15] because it is easier
to generate, requiring solely the measurement of VC, FEV1
and DLco, and predicts survival more consistently
[10,13].
When analysing the effects of NAC on VC, DLco, maximal
exercise indices, and the CPI we found that in completers
none of the indices deteriorated significantly with NAC,
but most indices did with placebo; in non-completers the
majority of indices worsened at a much lesser extent with
NAC than with placebo. Importantly, we did not observe
divergent signals from the completers and non-compl-
eters subgroups regarding treatment effects. Correspond-
ingly, categorical changes in VC, DLco and CPI showed
globally significantly better results with NAC than with
placebo.
Our data indicate that the effects of NAC on VC, DLco and
CPI were significantly better if the baseline CPI was low (≤
50 points), i.e. in the less severe cases. This finding is in
line with findings from previous studies and may suggest
the presence of specific disease processes in severe disease
states [15-18].
With respect to the clinical relevance of the changes
observed several authors have demonstrated in IPF
cohorts that small changes of FVC or DLco during the first
6 to12 months eventually result in major survival differ-
ences during the following years [13,19-22]. Conse-
quently, small treatment effects achieved with high dose
NAC therapy may impact survival significantly in the long
run [23]. A long-term clinical trial testing NAC in IPF is
clearly warranted.
Regarding IPF mortality it should be noted that lung func-
tion deterioration could be documented before death
only in a minority of patients (26,7%), whereas the
majority of patients (53.3%) died with rapid deterioration
within three months of treatment not allowing for control
lung function measurements before death. This may
imply that a decline of lung function does not precede a
fatal disease exacerbation, as hypothesized previously
[22] or simply that the intervals at which control measure-
ments of lung function were scheduled were too long.
This should be considered in future studies. A considera-
ble number of patients died from coexisting cardiac dis-
ease. This observation should draw attention to potential
comorbidities like coronary artery and left heart diseases
as well as pulmonary hypertension associated with IPF
which may warrant specific treatment approaches [24].
There are limitations of our study. The completers/non-
completers groups used for comparisons do not represent
predefined and stratified subgroups. Therefore, the groups
differ e.g. with respect to baseline lung function. On the
other hand it is not surprising and reassuring that the non-
completer group presented worse baseline values. The
explorative statistical analysis presented here was done
without correction for multiple testing, thus limiting its
use for clinical decision making. Moreover, our data do
not allow firm conclusions to be drawn on whether the
treatment effects observed are contributable to NAC alone
or can be achieved only when using triple therapy of pred-
nisone, azathioprine, and high-dose NAC. Finally, it may
be argued that intention to treat is the only acceptable
study design; although we do not question this dictum for
the pivotal analysis, additional exploratory analyses, as
the one presented here, may allow a better understanding
of the data structure and robustness and may help to gen-
erate new hypothesis and should, therefore, also be made
accessible.
Conclusion
Taken together the data presented here corroborate the
results of the pivotal paper [7] and support the use of
high-dose NAC in patients with IPF. Although the effect
size appears relatively small, the lack of serious side effects
allows a positive risk-to-benefit assessment. Notably, our
present analysis suggests that patients with less progressed
disease (CPI ≤ 50 points) may have a more favourable
response. Consequently, "triple therapy" - prednisone,
azathioprine plus high-dose NAC - is a seizable treatment
option for IPF patients. Referring to the available evidence
the recent ILD Guideline published by the British Thoracic
Society incorporated a weak recommendation (C) in
favour of high-dose NAC in combination with prednisone
and azathioprine for IPF patients [25].
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